Atrial fibrillation (AF) can lead to significant mortality, morbidity, and cost.1, 2 Long‐term prophylaxis with anticoagulation therapy is recommended to prevent stroke and systemic embolization in patients with AF presenting an independent risk factor for stroke.3 Four non vitamin‐K antagonists oral anticoagulants (NOACs) are currently available: the direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban) and the direct factor IIa inhibitor (dabigatran). This evidence concerns the gene F10 and atrial fibrillation.